TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.

Autor: Chan TY; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Egbert CM; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Maxson JE; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Siddiqui A; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., Larsen LJ; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Kohler K; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Balasooriya ER; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Pennington KL; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Tsang TM; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Frey M; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Soderblom EJ; Proteomics and Metabolomics Shared Resource, Duke University School of Medicine, Durham, NC, USA., Geng H; Department of Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA., Müschen M; Department of Systems Biology, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA., Forostyan TV; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., Free S; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., Mercenne G; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., Banks CJ; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Valdoz J; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Whatcott CJ; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., Foulks JM; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., Bearss DJ; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., O'Hare T; Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake, City, UT, USA., Huang DCS; The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia., Christensen KA; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Moody J; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA., Warner SL; Sumitomo Dainippon Pharma Oncology, Lehi, UT, USA., Tyner JW; Division of Hematology & Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.; Department of Cell, Developmental & Cancer Biology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Andersen JL; Fritz B. Burns Cancer Research Laboratory, Brigham Young University, Provo, UT, USA. jandersen@chem.byu.edu.; Department of Chemistry and Biochemistry, Brigham Young University, Provo, UT, USA. jandersen@chem.byu.edu.

Publikováno v: Nature communications [Nat Commun] 2021 Sep 09; Vol. 12 (1), pp. 5337. Date of Electronic Publication: 2021 Sep 09.

Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer.

Autor: Taverna JA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas., Hung CN; Department of Life Science, Tunghai University, Taichung, Taiwan.; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., DeArmond DT; Department of Cardiothoracic Surgery, University of Texas Health Science Center, San Antonio, Texas., Chen M; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Lin CL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Osmulski PA; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Gaczynska ME; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Wang CM; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Lucio ND; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Chou CW; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Chen CL; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Nazarullah A; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas., Lampkin SR; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas., Qiu L; Department of Pathology, University of Texas Health Science Center, San Antonio, Texas., Bearss DJ; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Warner S; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Whatcott CJ; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Mouritsen L; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Wade M; Tolero Pharmaceuticals, Department of Biomarker and Drug Discovery, Lehi, Utah., Weitman S; Institute for Drug Development, University of Texas Health Science Center, San Antonio, Texas., Mesa RA; Division of Hematology and Oncology, Department of Medicine, University of Texas Health Science Center, San Antonio, Texas., Kirma NB; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas., Chao WT; Department of Life Science, Tunghai University, Taichung, Taiwan. huangt3@uthscsa.edu wtchao@thu.edu.tw., Huang TH; Department of Molecular Medicine, University of Texas Health Science Center, San Antonio, Texas. huangt3@uthscsa.edu wtchao@thu.edu.tw.

Publikováno v: Cancer research [Cancer Res] 2020 Apr 01; Vol. 80 (7), pp. 1551-1563. Date of Electronic Publication: 2020 Jan 28.

Inhibition of ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic cancer.

Autor: Whatcott CJ; Molecular Medicine Division, The Translational Genomics Research Institute, Phoenix, Arizona, United States of America., Ng S; Molecular Medicine Division, The Translational Genomics Research Institute, Phoenix, Arizona, United States of America., Barrett MT; Mayo Clinic Cancer Center, Scottsdale, Arizona, United States of America., Hostetter G; Laboratory of Analytical Pathology, The Van Andel Research Institute, Grand Rapids, MI, United States of America., Von Hoff DD; Molecular Medicine Division, The Translational Genomics Research Institute, Phoenix, Arizona, United States of America., Han H; Molecular Medicine Division, The Translational Genomics Research Institute, Phoenix, Arizona, United States of America.

Publikováno v: PloS one [PLoS One] 2017 Aug 25; Vol. 12 (8), pp. e0183871. Date of Electronic Publication: 2017 Aug 25 (Print Publication: 2017).

Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer.

Autor: Whatcott CJ; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona. cwhatcott@tgen.org hhan@tgen.org., Diep CH; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona., Jiang P; Halozyme Therapeutics, San Diego, California., Watanabe A; Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona., LoBello J; Integrated Cancer Genomics Division, The Translational Genomics Research Institute, Phoenix, Arizona., Sima C; Computational Biology Division, The Translational Genomics Research Institute, Phoenix, Arizona., Hostetter G; Laboratory of Analytical Pathology, The Van Andel Research Institute, Grand Rapids, Michigan., Shepard HM; Halozyme Therapeutics, San Diego, California., Von Hoff DD; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona., Han H; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona. cwhatcott@tgen.org hhan@tgen.org.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2015 Aug 01; Vol. 21 (15), pp. 3561-8. Date of Electronic Publication: 2015 Feb 18.

Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look.

Autor: Whatcott CJ; Clinical Translational Research Division, The Translational Genomics Research Institute, Phoenix, Arizona, USA. cwhatcott@tgen.org, Han H, Posner RG, Hostetter G, Von Hoff DD

Publikováno v: Cancer discovery [Cancer Discov] 2011 Sep; Vol. 1 (4), pp. 291-6.